J. Wiezorek

Rapid conversion to high xanthine oxidase activity in viable Kupffer cells during hypoxia.

D. Brown, J. Wiezorek, C. Brass, 1994, The Journal of clinical investigation.

Abstract LB-174: Use of massively parallel, next-generation sequencing to identify gene mutations beyondERASthat predict response to panitumumab in a randomized, phase 3, monotherapy study of metastatic colorectal cancer (mCRC)

Y. Humblet, S. Patterson, M. Peeters, 2010 .

Analysis of KRAS/NRAS and BRAF mutations in the phase III PRIME study of panitumumab (pmab) plus FOLFOX versus FOLFOX as first-line treatment (tx) for metastatic colorectal cancer (mCRC).

Scott D. Patterson, Josep Tabernero, Jean-Yves Douillard, 2013 .

Health-related quality of life in patients with metastatic colorectal cancer treated with panitumumab in first- or second-line treatment

J. Douillard, M. Peeters, J. Wiezorek, 2011, British Journal of Cancer.